8-K: Phoenix Biotech Acquisition Corp. Amends Merger Agreement, Secures $2 Million PIPE Financing

Phoenix Biotech Acquisition Corp. has amended its business combination agreement with CERo Therapeutics, Inc., removing the minimum cash condition and securing a $2 million PIPE financing.

Summary

• Phoenix Biotech Acquisition Corp. has amended its business combination agreement with CERo Therapeutics, Inc., removing the minimum cash condition.
• The amendment also modifies stock-price based milestones for earn-out targets, resetting them to 125% and 150% of the conversion price of Series A Preferred Stock, respectively.
• The number of Class A common shares issuable to CERo stockholders has increased from 4,651,704 to 5,000,000, in addition to potential earn-out shares and shares issuable upon exercise of rollover options or warrants.
• The Company has entered into a securities purchase agreement for a $2 million PIPE financing, involving the issuance of Series A convertible preferred stock and warrants.
• The warrants are exercisable for cash at a price equal to the greater of $9.20 or the closing price of the Common Stock on the trading day immediately prior to the Subscription Date.
• The exercise period for the warrants begins six months after the issuance date and expires on the third anniversary of the initial exercisability date.
• The Series A Preferred Stock has a stated value of $1,000 per share and ranks senior to all capital stock of the Company unless the Required Holders consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series A Preferred Stock.
• The Series A Preferred Stock is convertible into Common Stock at a fixed conversion price of $10.00, subject to adjustment.
• The conversion price may be lowered by the Company with the written consent of the Required Holders.
• The conversion price will automatically lower to the Adjustment Price if 90 or 180 days after the Stockholder Approval Date or the effective date of the registration statement, the Conversion Price is greater than the greater of $1.00 and the Market Price.
• The Series A Preferred Stock is subject to a 19.99% conversion limitation unless stockholder approval is obtained.
• CERo has been selected as a finalist for subsidized funding of $4 to $6 million for a clinical trial of its lead product candidate.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The PIPE financing and potential grant are positive, but the removal of the minimum cash condition and the potential dilution from warrants are negative. The overall sentiment is neutral to slightly positive.

Positives

• The removal of the minimum cash condition may facilitate the closing of the business combination.
• The PIPE financing provides $2 million in capital to New CERo.
• The potential grant of $4 to $6 million for CERo's clinical trial could significantly reduce development costs.
• The reset of the earn-out targets may make them more achievable.

Negatives

• The conversion of the Series A Preferred Stock is subject to a 19.99% limitation unless stockholder approval is obtained, which could delay full conversion.
• The warrants require buy-in payments for failure to deliver shares upon exercise, which could create a liability for the Company.
• The PIPE financing includes warrants that could cause dilution to existing shareholders.

Risks

• The approval of the potential grant is subject to certain conditions, approvals and other uncertainties.
• The business combination is subject to various risks and uncertainties, including regulatory approvals and stockholder approval.
• The Company may not be able to maintain the listing of the combined companys securities on the stock exchange.
• The Company may not be able to complete any private placement financing or may complete it with terms unfavorable to the Company.
• The Company may not realize the anticipated benefits of the proposed business combination and related transactions.
• The Company may face risks related to the rollout of CERos business strategy and the timing of expected business milestones.
• The Company may face risks related to competition and the ability to grow and manage growth.
• The Company may face risks related to domestic and international political and macroeconomic uncertainty.
• The Company may face risks related to biotechnology, industry and regulations.
• The Company may face risks related to the amount of redemption requests made by the Companys public stockholders.

Future Outlook

The document includes forward-looking statements regarding the proposed business combination, related transactions, and the use of cash proceeds, but these are subject to various risks and uncertainties.

Industry Context

This announcement reflects a common strategy in the biotech industry where special purpose acquisition companies (SPACs) merge with private companies to gain public market access and secure funding for development programs. The amendment to the merger agreement and the PIPE financing are typical steps in such transactions.

Comparison to Industry Standards

• The use of earn-out provisions and PIPE financing is a common practice in SPAC mergers, particularly in the biotech sector.
• The specific terms of the earn-out targets (125% and 150% of the conversion price) are within the range of what is seen in similar transactions, but the specific values will depend on the conversion price of the Series A Preferred Stock.
• The $2 million PIPE financing is relatively small compared to some biotech SPAC mergers, which can range from tens to hundreds of millions of dollars, but is not unusual for smaller transactions.
• The potential grant of $4 to $6 million is a significant amount for a single clinical trial and could be a major boost for CERo's development program, if secured.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Shareholders may benefit from the potential growth of the combined company.
• Employees of both companies may experience changes due to the merger.
• Customers of CERo may benefit from the increased funding for research and development.
• Creditors of both companies may be affected by the terms of the merger and financing.

Next Steps

• The Company will need to obtain stockholder approval for the issuance of shares exceeding the 19.99% limitation.
• The Company will need to complete the business combination with CERo Therapeutics, Inc.
• CERo will need to secure the subsidized funding for its clinical trial.
• The Company will need to file a registration statement to register the shares of Common Stock underlying the Series A Preferred Stock and Warrants within 45 days after the closing of the Securities Purchase Agreement and to have such registration statement effective within 75 days of such closing.

Key Dates

Keywords

business combination, PIPE financing, convertible preferred stock, warrants, earn-out, clinical trial, biotech, merger, acquisition, capital raise